20-F: Polyrizon Reports Increased Losses Amid R&D Expansion

Polyrizon Ltd. reported a significant increase in net loss to $3.3 million in 2025, driven by expanded research and development activities and administrative costs, while securing substantial capital for future operations.

Summary

• Net loss increased to $3.335 million for the year ended December 31, 2025, compared to $1.545 million in 2024.
• Operating loss rose to $6.249 million in 2025 from $1.302 million in 2024, reflecting increased operational scale.
• Research and development expenses surged by 299% to $2.133 million in 2025, up from $0.534 million in 2024, primarily due to increased activity post-IPO.
• General and administrative expenses increased by 412% to $4.116 million in 2025 from $0.768 million in 2024, also attributed to post-IPO activity and a $0.464 million business email compromise theft loss.
• The company has not generated any revenue from product sales to date and does not anticipate doing so in the near future.
• Cash and cash equivalents stood at $1.306 million as of December 31, 2025, with additional bank deposits of $16.2 million, providing a working capital of $12.4 million.
• Management believes existing financial resources are sufficient to fund operations through March 2030.
• The company completed a private placement in March 2025, raising approximately $17.0 million gross, and a registered direct offering in December 2025, raising approximately $4.97 million gross.
• Preclinical studies for NASARIX (nasal allergy blocker) were initiated in Q2 2025, with pivotal clinical trials expected to commence in Q3 2026.
• PL-16 (influenza blocker) preclinical safety trials began in Q2 2025, with feasibility clinical trials planned for Q3 2027 and pivotal clinical trials for Q3 2028.
• Feasibility studies for the Trap & Target (T&T) platform with corticosteroids, benzodiazepines, and naloxone were initiated in Q4 2024 and are ongoing through Q3 2026.
• Preclinical studies for the T&T platform are expected to begin in Q3 2026, with Phase I clinical trials for the leading T&T candidate planned for Q4 2028.
• A development agreement was signed with Clearmind Medicine Inc. to develop an intranasal formulation of MEAI for addiction and CNS conditions.
• An exclusive patent license agreement was entered into with SciSparc Ltd. for the SCI-160 platform for pain treatment, with potential milestone payments up to $3.32 million and 5% royalties on net sales.
• The company was the victim of a business email compromise theft in October 2025, resulting in a $0.464 million loss, and a subsequent attempted fraud in December 2025.
• An internal control over financial reporting assessment concluded that controls were effective as of December 31, 2025, despite the cyber incident, but disclosure controls and procedures were not effective.
• The company's headquarters and operations in Israel are subject to political, economic, and military instability, including ongoing conflicts, which could adversely affect business conditions.
• A non-binding MOU was signed on February 3, 2026, to acquire a 51% stake in Arrow Aviation Ltd. for approximately $5.8 million, involving convertible notes and mutual call/put options.
• On February 28, 2026, a joint military operation by the United States and Israel against Iran commenced, with Iran retaliating, and Hezbollah joining attacks against Israel, leading to updated safety guidelines and potential economic impact in Israel.
• The company's ordinary shares underwent reverse stock splits of 1-for-250 on May 27, 2025, and 1-for-6 on November 28, 2025.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report. While significant capital raises provide a strong liquidity runway and preclinical progress is noted, the substantial increase in losses, early stage of all product candidates, and geopolitical risks in Israel temper the overall sentiment. The cyber fraud incident and ineffective disclosure controls are also concerns.

Positives

• Successfully raised substantial additional funding through a $17.0 million private placement and a $4.97 million registered direct offering in 2025, significantly bolstering liquidity.
• Maintained a strong liquidity position with $1.306 million in cash and cash equivalents and $16.2 million in bank deposits as of December 31, 2025, projected to fund operations through March 2030.
• Achieved key preclinical and operational milestones for NASARIX, including positive allergen-blocking performance, strong tolerability in human nasal tissue, manufacturing scale-up for clinical trial material, and initiation of a human-factors/usability study.
• Submitted a Pre-Request for Designation (Pre-RFD) to the FDA for PL-16, initiating formal regulatory discussion for its influenza blocker candidate.
• Demonstrated broad-spectrum viral blocking activity for PL-16 in in vitro studies, preventing virus-induced cytopathic effects and maintaining high cell viability.
• Advanced the Trap & Target (T&T) platform with feasibility studies for corticosteroids, benzodiazepines, and naloxone, showing promising ex-vivo mucoadhesion and nasal deposition for naloxone formulations.
• Entered into a development agreement with Clearmind Medicine Inc. for a proprietary intranasal non-hallucinogenic psychedelic formulation for CNS conditions.
• Secured an exclusive, worldwide, royalty-bearing license from SciSparc Ltd. for its SCI-160 platform for pain treatment, expanding the product pipeline.
• The company's internal control over financial reporting was assessed as effective as of December 31, 2025.

Negatives

• Incurred significant net losses, increasing to $3.335 million in 2025 from $1.545 million in 2024.
• Operating losses substantially widened to $6.249 million in 2025 from $1.302 million in 2024.
• Experienced a business email compromise theft in October 2025, resulting in a $0.464 million loss of funds that could not be recovered to date.
• Disclosure controls and procedures were deemed not effective as of December 31, 2025.
• The company has never generated revenue from product sales and does not anticipate doing so in the near future, indicating a prolonged path to profitability.
• All product candidates are in early stages of development (preclinical or early clinical trials), with significant time and cost required for regulatory approval and commercialization.
• The company has not conducted a pre-submission meeting with the FDA's CDRH to confirm the potential for the Class II medical device path under a de novo classification request for its PL-16 product, which could lead to a lengthier approval process.
• The company's operations are located in Israel, exposing it to political, economic, and military instability, including ongoing conflicts, which could adversely affect business conditions.
• The recent military operations in Israel and retaliatory attacks by Iran and Hezbollah, commencing February 28, 2026, create significant geopolitical risk and uncertainty for the company's operations and the Israeli economy.

Risks

• Significant losses since inception and anticipation of continued losses for the foreseeable future, with no revenue from product sales yet.
• Need to raise substantial additional funding, which may not be available on acceptable terms or at all, potentially leading to curtailment or discontinuation of development efforts.
• Dependence on enrollment of patients in upcoming clinical trials, which may be difficult due to various factors, delaying or preventing trial completion.
• Uncertainty and potential delays in receiving necessary regulatory clearances or approvals for product candidates (e.g., FDA, EMA), which could adversely affect business growth.
• Risk that the FDA may deny the Class II medical device path under a de novo classification request for PL-16, requiring a lengthier PMA pathway.
• Legislative or regulatory reforms in the U.S. or EU may make it more difficult and costly to obtain regulatory approvals or to manufacture, market, or distribute products.
• Heavy dependence on the success of C&C product candidates, including obtaining regulatory approval.
• Regulatory approval processes are lengthy, time-consuming, and unpredictable; failure to obtain approvals could lead to business failure.
• If the FDA does not conclude that the T&T platform product candidate satisfies Section 505(b)(2) requirements, or if the hybrid application pathway in the EU is unavailable, approval could take significantly longer and cost more.
• Novelty of C&C and T&T technologies makes it difficult to accurately predict development time and cost, and regulatory approval.
• Lack of prior experience in conducting pivotal clinical trials as an organization, which may hinder successful execution for T&T platform candidates.
• Product candidates may cause undesirable side effects, delaying or preventing regulatory approval, limiting commercial profile, or resulting in negative consequences post-approval.
• Exposure to U.S. federal and state healthcare fraud and abuse laws, false claims laws, physician payment transparency laws, and health information privacy and security laws, with potential for substantial penalties for non-compliance.
• Intense competition in an environment of rapid technological change from major multinational medical device and pharmaceutical companies.
• Misuse or off-label use of product candidates could harm reputation, lead to liability suits, or result in costly investigations, fines, or sanctions.
• Reliance on third parties (CROs, manufacturers) to conduct preclinical studies, clinical trials, and manufacturing, with risks of failure to meet deadlines, comply with regulations, or provide sufficient quantities/quality of materials.
• Inability to obtain and maintain effective patent rights or protect trade secrets/know-how could impair competitive position.
• Potential involvement in lawsuits to protect or enforce intellectual property, which could be expensive, time-consuming, and unsuccessful.
• Claims that employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties, or claims challenging inventorship of intellectual property.
• Need to expand the organization and potential difficulties in managing this growth, disrupting operations.
• Limited resources and capital necessitate prioritization of certain product candidates, which may prove to be incorrect decisions.
• Failure to identify, discover, or license additional product candidates could materially adversely affect the business.
• Risk of misconduct or improper activities by employees and independent contractors, including non-compliance with regulatory standards and fraud.
• Inability to enforce covenants not to compete under applicable employment laws, allowing competitors to benefit from former employees' expertise.
• Scrutiny of sustainability and ESG initiatives could increase costs or adversely impact the business.
• Adverse effects from current or future unfavorable economic and market conditions, including inflation and interest rate increases, and adverse developments with financial institutions.
• Risks associated with international expansion, including conflicting laws, regulatory approvals, intellectual property enforcement, and political/economic instability.
• Lack of a marketing and sales organization; inability to establish or partner for these capabilities could prevent revenue generation.
• Significant regulatory oversight in manufacturing, with potential delays or disruptions if processes or facilities are not compliant with cGMP.
• Limited sales if product candidates fail to achieve broad market acceptance by physicians, patients, and third-party payors.
• Difficulty in profitably selling products if coverage and reimbursement are limited by government authorities and/or third-party payor policies.
• Significant risk of clinical trial and/or product liability, with potential for insufficient insurance coverage.
• Executive officers, directors, and principal shareholders maintain significant control over matters submitted to shareholders for approval.
• U.S. shareholders may suffer adverse tax consequences if the company is characterized as a Passive Foreign Investment Company (PFIC).
• As a foreign private issuer, the company follows certain home country corporate governance practices instead of Nasdaq requirements, potentially offering less protection to investors.
• Risk of delisting from the Nasdaq Capital Market if continued listing requirements are not met, negatively impacting share price and access to capital markets.
• Computer system failures, cyber attacks, or deficiencies in cybersecurity, as evidenced by the recent business email compromise theft, could disrupt operations and lead to losses.
• Dependence on retaining senior management and attracting/retaining qualified personnel.
• No anticipation of paying cash dividends in the foreseeable future, making capital appreciation the sole source of gain for investors.
• Potential decline in share price and trading volume if securities or industry analysts cease coverage or publish negative reports.
• Geopolitical risks in Israel, including ongoing military conflicts and regional instability, could adversely affect business conditions and the market price of ordinary shares.
• Potential for Israeli law provisions and articles of association to delay, prevent, or impede mergers or acquisitions.

Future Outlook

Polyrizon anticipates continued net losses for the foreseeable future as it advances its C&C and T&T product candidates through preclinical and clinical development. The company expects to initiate pivotal clinical trials for NASARIX in Q3 2026, feasibility clinical trials for PL-16 in Q3 2027, and Phase I clinical trials for the leading T&T candidate in Q4 2028. Management believes current cash and cash equivalents will fund operations through March 2030, but acknowledges the need for additional financing, which may not be available on favorable terms. The company also plans initial testing to explore the potential of its SCI-160 platform when combined with T&T technology in Q3 2026.

Management Comments

• Management believes that the company's existing financial resources will be sufficient to sustain its planned operations for at least the next twelve months.
• Management believes that the company's experienced results-oriented management team, promising IP portfolio, scalable robust business model and multiple product candidates validating its technologies gives it a distinct advantage in the marketplace.
• Management believes that the holistic knowhow of our group will strongly contribute to a successful path from clinical development, regulatory approvals and commercialization of our product candidates.
• Management believes that the company's C&C product candidates will be regulated as Class II medical devices due to their physical barrier mode of action.
• Management believes that the T&T hydrogel technology can be compatible with drugs related to the central nervous system and significantly improve their bioavailability.

Industry Context

StockSavvy.ai notes that Polyrizon operates in the intensely competitive medical device and pharmaceutical industries, characterized by rapid technological change. The company is targeting significant market opportunities in nasal sprays, including the global nasal spray market projected to reach $70.17 billion by 2034 (CAGR of 8.90%), the cold and cough remedies market projected to reach over $9.7 billion by 2030 (CAGR of 5.2%), and the allergic rhinitis drugs market projected to reach $7.31 billion by 2032 (CAGR of 4.94%). The global allergy immunotherapy market is also expected to reach $4.9 billion by 2033 (CAGR of 10.4%). For its T&T platform, Polyrizon is addressing the intranasal drug delivery market, projected to reach $120.83 billion by 2032 (CAGR of 7.9%), with specific focus on intranasal corticosteroids ($12.03 billion by 2035, CAGR of 4.8%), benzodiazepines ($5.4 billion by 2035, CAGR of 3.0%), and naloxone ($2.7 billion by 2032, CAGR of 9.20% for global naloxone, and $7,066.49 billion by 2035 for naloxone spray, CAGR of 24.17%). The company's strategy to focus on non-invasive, fast-acting nasal hydrogels aligns with patient preferences for ease of administration and avoidance of needles, as highlighted by industry reports.

Comparison to Industry Standards

• Polyrizon's NASARIX product candidate is pursuing the 510(k) pathway, referencing predicate devices such as Alzair, Nasalese, and Bentrio. The FDA submission and clearance process for these predicate devices took 86 and 140 days, respectively, which provides a benchmark for Polyrizon's expected regulatory timeline.
• For its PL-16 product candidate, Polyrizon found no direct predicate devices in the FDA database, necessitating a De Novo Classification request. This indicates a more novel product compared to existing market offerings, potentially leading to a longer and more rigorous approval process than a standard 510(k) pathway.
• In the intranasal naloxone market, Polyrizon's T&T hydrogel formulation demonstrated significantly stronger mucosal retention ex-vivo compared to a marketed intranasal naloxone product, with statistical significance (p < 0.0001). This suggests a potential competitive advantage in drug residence time.
• Despite improved mucoadhesion, the permeation rate of naloxone from Polyrizon's formulation was comparable to the commercial reference product, indicating that enhanced retention did not impede drug diffusion, which is a positive outcome for drug delivery efficiency.
• Nasal deposition studies showed Polyrizon's formulation achieved higher deposition in the nasal vestibule (71.5% vs. 54.9% for reference product) and lower deposition in the lower turbinate region (5.4% vs. 20.4%) compared to a commercial reference product. This targeted deposition profile is crucial for the intended mechanism of action as a barrier-forming spray.
• The company's focus on already approved APIs (corticosteroids, benzodiazepines, and naloxone) for its T&T platform aims to shorten clinical and regulatory processes towards 505(b)(2) approval, a strategy common among companies seeking to leverage existing safety and efficacy data for reformulations, potentially accelerating market entry compared to entirely new chemical entities.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently subject to any legal proceedings.

Related Party Transactions

• June 2023, December 2023, and May 2024 Share Purchase Agreements: Issued 513,878 Ordinary Shares for $582,000 to principal shareholders, including Xylo Technologies Ltd. (XYLO), Raul Srugo (then director), and his immediate family members. XYLO paid a portion with its American Depositary Shares.
• Convertible Loan with XYLO (February 4, 2023): XYLO extended an $80,000 loan at 4% annual interest, which converted into 88,216 Ordinary Shares on May 12, 2024.
• Convertible Loan with Reuven Srugo Construction Company Ltd. (February 4, 2023): Reuven Construction (owned by Raul Srugo and family) extended a $100,000 loan at 4% annual interest, which converted into 110,270 Ordinary Shares on May 12, 2024.
• August 2024 CLA: L.I.A Pure Capital Ltd. and Reuven Srugo Construction Company Ltd. provided a $60,000 convertible loan at 4% annual interest, which was repaid in connection with the October 2024 IPO.
• Taurus Transaction (October 2025): Purchased securities of Taurus Gold Corp. for $465,139 (CAD 651,000) and $47,647 (CAD 66,639). Oz Adler, Chairman of Polyrizon's board, had a personal interest due to his investment in Taurus.
• Investment in Viewbix (December 2025 January 2026): Acquired 82,000 shares of Viewbix Inc. for $124,640. Tomer Izraeli (CEO) and Tidhar Turgeman (CTO) had a personal interest as shareholders of Cliniquantum Ltd., which Viewbix is expected to acquire a controlling interest in.
• Employment and Consulting Agreements with Executive Officers: Customary noncompetition, confidentiality, and invention assignment provisions. Indemnification agreements with executive officers and directors.
• Options and RSUs: Granted options and RSUs to employees, officers, service providers, and directors, with certain acceleration provisions upon change of control.

Stakeholder Impact

• Shareholders: Dilution from recent capital raises and potential future financings. Potential for capital appreciation is the sole source of gain as no dividends are anticipated. Geopolitical risks and cybersecurity incidents could negatively impact share price. The ineffectiveness of disclosure controls could affect transparency.
• Employees: Continued employment and potential equity-based compensation. Exposure to Israeli labor laws and non-compete clauses. The company's growth plans suggest potential for increased headcount.
• Customers/Patients: Potential for new non-invasive medical device solutions for allergies, influenza, and targeted drug delivery. Delays in regulatory approval could delay access to these products.
• Suppliers/Partners: Continued reliance on third-party manufacturers and CROs. New collaboration agreements (e.g., Clearmind, SciSparc) indicate expanded partnerships. The business email compromise incident highlights risks in financial transactions with partners.
• Creditors: The company's strong liquidity position from recent capital raises reduces immediate credit risk. However, ongoing losses and the need for future financing could impact long-term creditworthiness.

Next Steps

• Initiate pivotal clinical trial of C&C product candidates (NASARIX) in the third quarter of 2026.
• Seek regulatory and marketing approvals for any product candidates that successfully complete clinical trials.
• Advance preclinical and research and development programs for other product candidates.
• Identify, assess, acquire, license, and/or develop other product candidates.
• Manufacture cGMP material for clinical trials or potential commercial sales.
• Establish a sales, marketing, and distribution infrastructure to commercialize any approved product candidates.
• Hire additional personnel and invest in infrastructure to support public company operations and product development.
• Enter into agreements to license intellectual property from third parties.
• Develop, maintain, protect, and expand the intellectual property portfolio.
• Initiate feasibility clinical trials for PL-16 in the third quarter of 2027.
• Initiate pivotal clinical trials for PL-16 in the third quarter of 2028.
• Submit De Novo Classification requests for PL-16 following clinical trials.
• Initiate preclinical studies for the T&T platform in the third quarter of 2026.
• Plan Phase I clinical trials for the leading T&T technology product candidate for the fourth quarter of 2028.
• Start initial testing to explore the potential of the SCI-160 platform when combined with the T&T technology in the third quarter of 2026.
• Schedule a pre-submission meeting with the FDA's CDRH in the second half of 2026 to confirm the regulatory path for PL-16.
• Pursue recovery of funds lost due to business email compromise theft and cooperate with law enforcement authorities.
• Address the identified deficiencies in disclosure controls and procedures.

Key Dates

Recommendation

Polyrizon is a development-stage biotech company with promising early-stage product candidates and a strong cash position following recent capital raises, which provides a runway through March 2030. This liquidity is crucial for funding extensive R&D and clinical trials. However, the company faces significant risks inherent in biotech development, including regulatory uncertainties, intense competition, and a prolonged path to profitability with no current revenue. The substantial increase in net and operating losses, coupled with the recent cyber fraud incident and ineffective disclosure controls, raises concerns about operational execution and financial oversight. Geopolitical instability in Israel further adds to the risk profile. Given the early stage of development for all product candidates and the high-risk nature of the industry, a 'hold' recommendation is appropriate. Investors should monitor clinical trial progress, regulatory milestones, and improvements in internal controls, while acknowledging the significant speculative elements of this investment.

Keywords

Biotech, Nasal Sprays, Hydrogel Technology, Medical Device, Drug Delivery, NASARIX, PL-16, Trap & Target (T&T), Allergies, Influenza, Opioid Antagonist, Naloxone, Benzodiazepines, Corticosteroids, Preclinical Studies, Clinical Trials, FDA Approval, SEC Filing, Form 20-F, Israel, Capital Raise, Cybersecurity, Intellectual Property